Vivo Capital’s Aligos Therapeutics ALGS Stock Holding History

Vivo Capital’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,199	Closed	-$84.1K	–	43
2025 Q1	$84.1K	Sell	10,199 -131,680	-93%	-$2.89M	0.01%	39
2024 Q4	$5.65M	Hold	141,879	–	–	0.63%	32
2024 Q3	$1.23M	Sell	141,879 -2	-0%	-$25	0.1%	38
2024 Q2	$1.24M	Hold	141,881	–	–	0.11%	36
2024 Q1	$3.48M	Hold	141,881	–	–	0.27%	38
2023 Q4	$2.36M	Hold	141,881	–	–	0.19%	43
2023 Q3	$2.65M	Hold	141,881	–	–	0.29%	43
2023 Q2	$3.44M	Hold	141,881	–	–	0.24%	41
2023 Q1	$3.1M	Hold	141,881	–	–	0.22%	38
2022 Q4	$3.38M	Hold	141,881	–	–	0.39%	39
2022 Q3	$3.9M	Hold	141,881	–	–	0.43%	42
2022 Q2	$4.29M	Hold	141,881	–	–	0.43%	40
2022 Q1	$7.63M	Hold	141,881	–	–	0.53%	36
2021 Q4	$42.1M	Hold	141,881	–	–	2.54%	9
2021 Q3	$55M	Hold	141,881	–	–	2.47%	10
2021 Q2	$72.3M	Hold	141,881	–	–	3.13%	9
2021 Q1	$80.7M	Hold	141,881	–	–	2.83%	10
2020 Q4	$98.1M	Buy	+141,881	New	+$69.1M	4.38%	6

Other funds holding ALGS

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RAM

Readystate Asset Management Chicago, Illinois $2.93B AUM 18.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Vivo Capital's ALGS Position: Q2 2025 in Review

Vivo Capital sold out of Aligos Therapeutics (ALGS) in Q2 2025, closing a stake of 10,199 shares — an estimated $84.1K sold.

Vivo Capital first reported a position in ALGS in Q4 2020 and held it in 18 quarters. The position peaked at $98.1M in Q4 2020. 37 funds tracked by Wall St. Rank hold ALGS as of Q2 2025.

Vivo Capital reported no remaining Aligos Therapeutics position as of Q2 2025 after selling out during the quarter.
Vivo Capital sold 10,199 Aligos Therapeutics shares in Q2 2025, an estimated $84.1K.
Vivo Capital first reported a position in Aligos Therapeutics in Q4 2020 and held it in 18 quarters.
Vivo Capital's Aligos Therapeutics position peaked at $98.1M in Q4 2020.
37 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2025.

Based on Vivo Capital's 13F filing for Q2 2025, filed 14 Aug 2025.